Renpei Kato

Has grant

Lecturer

Iwate Medical University

Japan

Research Interests

Explore related searches

Professors in Japan

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Renpei Kato is a Lecturer at Iwate Medical University in Japan. His research focuses on renal cell carcinoma, including treatments such as nivolumab and cabozantinib, as well as the effectiveness of combination therapies and the impact of genetic factors on clinical outcomes. He has contributed to multiple publications that explore therapeutic responses and strategies in oncology.

Recent Grants

Grant: Close

Grants-in-Aid for Scientific Research

Open Date: 2022-04-01

Close Date:

Grant: Close

Grant-in-Aid for Young Scientists

Open Date: 2019-01-01

Close Date: 2021-01-01

Articles (10)

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (2)

Shuya Kandori

Lecturer

University of Tsukuba

JAPAN

View details

Mitsugu Kanehira

Iwate Medical University

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Renpei Kato

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (10)

Pathological Complete Response to Preoperative Nivolumab Plus Cabozantinib for Renal Cell Carcinoma With Inferior Vena Cava Thrombus: A Case Report.

Clinical impact of early response to first-line VEGFR-TKI in patients with metastatic renal cell carcinoma on survival: A multi-institutional retrospective study

Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era – a multi-institutional retrospective study

Editorial Comment to Phase I/II study of multipeptide cancer vaccine IMA901 after single-dose cyclophosphamide in Japanese patients with advanced renal cell cancer with long-term follow up.

Real-world effectiveness of nivolumab plus ipilimumab and second-line therapy in Japanese untreated patients with metastatic renal cell carcinoma: 2-year analysis from a multicenter retrospective clinical study (J-cardinal study).

Site-specific patterns of early response to nivolumab plus ipilimumab therapy in advanced renal cell carcinoma patients compared with tyrosine-kinase inhibitors.

Impact of germline HLA genotypes on clinical outcomes in patients with urothelial cancer treated with pembrolizumab.

Anti-PD-1/PD-L1 therapy for renal cell carcinoma: challenges in the development of predictive biomarkers.

A case of male perineal aggressive angiomyxoma with expressions of female hormone receptors.

Concurrent robot-assisted radical prostatectomy and robot-assisted partial nephrectomy for patients with synchronous prostate cancer and small renal tumor: A case series of five patients.

Collaborators (2)

Shuya Kandori

Mitsugu Kanehira

Make your next move.